Is BPC-157 Legal in Alabama? Federal Status, State Rules, and How to Get It

Can you legally get BPC-157 in Alabama?

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice. No FDA-approved drug contains it, and there is no US Pharmacopeia or National Formulary monograph for it [1]. Compounded drugs are not FDA-approved either: FDA does not review their safety, effectiveness or quality before marketing [4].

Federal compounding rules decide who may supply it. On FDA's list of nominated bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026), BPC-157 is in none of the three categories. Category 1 is the group FDA says it generally will not act against compounders for, if conditions are met, so that policy does not cover BPC-157 [2]. It is also not on FDA's list for outsourcing facilities (updated March 21, 2025) [5].

It was in category 2 of FDA's significant-safety-risk page from September 2023 until April 22, 2026, when it moved to a nominated-but-withdrawn table after the nominating groups withdrew their nominations. That move was not a finding of safety, and the page still carries FDA's stated concerns about immunogenicity, peptide-related impurities and insufficient safety information [8].

Alabama's own pharmacy and medical-board rules are set separately from these federal policies and are not described here.

What changed in 2026?

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation; news reports give the vote as 8 to 6 with 1 abstention. FDA's own reviewers had proposed that it not be added, citing poor chemical characterization, limited safety and immunogenicity data, and insufficient evidence for ulcerative colitis, the use FDA evaluated [1]. Advisory committees make non-binding recommendations, and adding BPC-157 to the list would need formal rulemaking [6][4].

On October 28, 2026 HHS filed a notice announcing a draft enforcement-discretion policy for six peptides, BPC-157 among them [3]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if conditions are met [3]. For BPC-157 the conditions include:

• BPC-157 acetate only, as a single active ingredient
• subcutaneous, intramuscular, oral or topical forms (nasal, rectal and intravenous are not listed)
• a patient-specific prescription
• a bulk substance from an FDA-registered manufacturer with a valid certificate of analysis [4]

The draft names pharmacies, federal facilities and physicians, not outsourcing facilities. The notice says the policy is not binding on HHS or the public, and HHS may revisit it [3].

What is known about safety?

FDA concluded there is insufficient clinical safety information to characterize BPC-157's safety profile, and found no human studies of it given orally, by subcutaneous injection, by nasal spray or on the skin [1]. Its adverse-event database search through December 4, 2025 found 3 reports, all injectable, and FDA said it cannot tell whether BPC-157 caused them [1]. A 2026 systematic review found 3 human studies in orthopaedic use, 30 patients, all of poor methodological quality, with certainty of evidence rated very low [9].

WADA names BPC-157 in S0, non-approved substances, prohibited at all times; the 2026 List has been in force since January 1, 2026 [7].